# A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

> **NCT00730236** · PHASE3 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** AEGR-733

## Key facts

- **NCT ID:** NCT00730236
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-09
- **Final completion:** 2011-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730236, "A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00730236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*